• AIM ImmunoTech highlighted a BioTuesdays feature on Ampligen as a maintenance therapy for metastatic pancreatic cancer.
• Final dosing finished in the DURIPANC trial combining Ampligen with AstraZeneca’s Imfinzi following first-line chemotherapy.
• Primary and secondary endpoint results have not been presented yet; reporting is pending as the program advances toward pivotal development.
• The strategy targets immune resistance to sustain disease control, aiming to extend survival and improve quality of life without new chemotherapy.
• Exploratory observations from a Netherlands named-patient program helped guide biomarker work, though they do not establish efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070914PRIMZONEFULLFEED9841161) on October 07, 2026, and is solely responsible for the information contained therein.